

Manulife Global Quality Growth (Ex-U.S.) Fund

Seeks: High total return

Use for: Core global ex-U.S. growth equity holding

Quality growth companies

Targeting high-quality, growing companies to potentially limit participation in falling markets while keeping pace in rising markets

A proven approach

Focusing on time-tested measures of free cash flow, organic growth, valuation, capital returns, and earnings expectations

Veteran portfolio management

With two decades of disciplined stock-picking experience, employing a rigorous process through every market environment

OPERATIONAL DETAILS

Base currency: U.S. dollar

Legal structure: UCITS

Domicile: Ireland

Settlement: Trade day + 3 days

Pricing: Daily

Dealing day cutoff: 4 p.m., U.S. Eastern time

Net assets (\$M): 172.60

Fiscal year end: 31 March

Ongoing charges figure (%):

Class I USD (acc): 1.05

MANAGED BY



John A. Boselli, CFA

On the fund since inception
Investing since 1996

WELLINGTON MANAGEMENT®

Long-established global asset manager investing across the equity, fixed-income, currency, and commodity markets, including multistrategy, specialty, and alternative investment approaches

INVESTMENT PROCESS

Screen stocks

The portfolio team screens the universe of non-U.S. stocks to select companies exhibiting the following quality, growth, and valuation characteristics:

- High organic revenue growth
- Superior quality business models
- Low free cash flow valuation
- Capital return to shareholders
- Improving fundamentals

Employ qualitative analysis

Companies that pass the initial screening are assessed to identify those with improving fundamentals, characterized by such attributes as industry dynamics, company positioning, management strategy, and earnings revisions.

Construct a portfolio

Weightings are determined by the manager's conviction level for each company.

Respond to macroeconomic changes

Market indicators are monitored to recognize turning points in macroeconomic cycles.


Sell discipline

Securities are sold when growth or quality metrics deteriorate, valuation upside declines, allocation to dividends or share repurchase changes, or earning revisions worsen.

SHARE CLASS INFORMATION

	Minimum investment	Sales charge	ISIN	CUSIP
Class I USD (acc)	\$1,000,000	None	IE00BD6G5F23	G5801G719

TEN LARGEST COUNTRIES¹ (%)



China	16.78
France	11.71
Taiwan	9.38
United Kingdom	9.30
Japan	8.84
Switzerland	8.69
Netherlands	7.65
Sweden	5.56
Denmark	4.63
Ireland	3.99

TOP TEN HOLDINGS¹ (%)

Taiwan Semiconductor Manufacturing Company, Ltd.	5.90
Tencent Holdings, Ltd.	5.02
Nestle SA	3.70
ASML Holding NV	3.26
AstraZeneca PLC	3.09
LVMH Moet Hennessy Louis Vuitton SE	2.67
Alibaba Group Holding, Ltd.	2.65
Recruit Holdings Company, Ltd.	2.53
Novo Nordisk A/S	2.46
Cellnex Telecom SA	2.34
TOTAL	33.61

MARKET CAP² (\$B)

	Fund	Benchmark
Median market cap	39.96	11.29
Weighted average market cap	165.54	137.44
Average market cap	97.10	26.30

KEY STATISTICS

	Fund	Benchmark
Number of holdings	55	1,163
P/E ratio (trailing) ³	29.9x	25.0x

AVERAGE ANNUAL TOTAL RETURNS (%)

	QTD	YTD	1 year	3 year	5 year	10 year	Since inception
Class I (acc)	6.61	10.08	38.60	14.50	—	—	17.63
MSCI AC World ex-USA Growth Index ⁴	6.60	6.52	33.68	13.23	—	—	14.92

CALENDAR YEAR RETURNS (%)

	2017	2018	2019	2020
Class I (acc)	37.37	-11.67	27.99	22.90
MSCI AC World ex-USA Growth Index ⁴	32.01	-14.43	27.34	22.20

The fund's inception date is 09/12/2016. Performance greater than 1 year is annualised and net of fees. Past performance is not indicative of future results and you may not get back what you invested. Changes in exchange rates may have an adverse effect.

IMPORTANT INFORMATION FOR INVESTORS

For Professional and/or Qualified Investors only (not to be used with or passed onto retail clients). In the UK Issued and approved by Manulife Investment Management (Europe) Limited. Registered in England No.02831891. Registered Office: One London Wall, London EC2Y 5EA. Authorised and regulated by the Financial Conduct Authority. In the EEA Issued and approved by Manulife Investment Management (Ireland) Limited. Registered office located Second Floor, 5 Earlsfort Terrace, Dublin 2, D02 CK83, Ireland.

This fund is a sub-fund of Manulife Investment Management I PLC, which is an open-ended umbrella company with segregated liability between its sub funds. Manulife Investment Management I PLC (company) has been authorized in Ireland as a UCITS fund pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulation 2011, as amended. Certain funds of the company have also been authorized for sale in certain EEA jurisdictions, the United Kingdom and Switzerland. No fund of this company has been authorized for sale in any other jurisdiction, and this material and any related materials may not be distributed or published in any jurisdiction where it would be contrary to local law or regulation. Please see www.manulifeim.com/institutional for more information, including where this fund is registered for sale. The information provided is not to be construed as an offer to buy or sell any financial instrument, nor does it constitute an offer or invitation to invest in any fund managed by Manulife Investment Management (Ireland) Limited, and has not been prepared in connection with any such offer.

The value of investments and resulting income may fall as well as rise, and you may get back less than you invested. International investing, especially in emerging markets, has additional risks, such as currency and market volatility and political and social instability. Hedging and other strategic transactions may increase volatility and result in losses of not successful. Please see the fund's prospectus or KIID for additional risks associated with this UCITS fund. Past performance does not guarantee future results.

Manulife Investment Management (Ireland) Limited is the distributor of the fund. Manulife Investment Management (Europe) Ltd. is the sub distributor of the fund. This fund may not be offered or sold to U.S. citizens or residents. Any decision to invest in this fund should be based on a review of the terms of the prospectus, including the relevant supplement, the relevant Key Investor Information Document (KIID), and the latest annual and semi-annual accounts, which are available in English at www.manulifeim.com/institutional.

The representative in Switzerland is ARM Swiss Representatives SA, Route de Cité-Ouest 2, 1196, Gland and the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, 1204 Geneva. The prospectus, the KIID, and the articles of association, as well as the semi-annual and annual reports can be obtained on request, free of charge, from the representative in Switzerland or on the website mentioned above.

¹ Listed holdings are a portion of the fund's total and may change at any time. They are not recommendations to buy or sell any security. Data is expressed as a percentage of net assets and excludes cash and cash equivalents. ² FactSet. Market capitalization is the value of a corporation determined by the market price of its issued and outstanding common stock.

³ FactSet. Price to earnings (P/E) is a valuation measure comparing the ratio of a stock's price with its earnings per share. ⁴ The MSCI All Country (AC) World ex-USA Growth Index tracks the performance of publicly traded large- and mid-cap stocks with higher forecasted growth rates in 22 developed markets and 24 emerging markets. It is not possible to invest directly in an index.